-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎WuXi AppTec content team editor Recently, NRG, an innovative neuroscience company targeting mitochondrial dysfunction Therapeutics has announced the completion of a £16 million Series A funding round
.
NRG is developing disease modification therapies based on mitochondrial biology to slow or halt the progression
of neurodegenerative diseases such as Parkinson's disease and amyotrophic lateral sclerosis (ALS).
The funding will be used to advance INDs
for its potential "first-in-class" brain-permeable small molecule therapy candidates, the press release said.
Parkinson's disease is one of the fastest-growing neurological disorders in the world and is caused
by the loss of specific dopamine-producing cells in the brain that control muscle movement.
ALS is a rare fatal neurodegenerative disease in which patients usually die
within 3-5 years of diagnosis.
Currently commercially available ALS disease-modifying therapies can prolong survival by about 3-6 months, and these patients urgently need disease-modifying drugs
that can further prolong survival.
Mitochondria are essential for maintaining the health of cells by
powering them.
There is plenty of evidence that mitochondrial failure, or dysfunction, is common
in many degenerative diseases.
In recent years, mitochondrial permeability transition pore (mPTP) has been implicated
in the formation of such diseases.
The micro-turn on of mPTP allows key related proteins that lead to Parkinson's disease and ASL to enter the mitochondria and release mitochondrial DNA into the
cytoplasm.
The immune system then recognizes this DNA as a foreign invader, leading to a large amount of inflammation and the death
of downstream neurons.
In preclinical disease models, inhibition of mPTP has been shown to protect neurons, reduce neuroinflammation, and prolong survival
.
mPTP is a key driver of Parkinson's disease and ALS disease pathology (Image: NRGTherapeutics).
NRG's preclinical pipeline includes small molecule candidate therapies
that inhibit mPTP through novel mechanisms of action.
This small molecule acts like a kind of biological "tape" that prevents the opening of mPTP and thus mitochondrial damage
.
In vitro studies have shown that the investigational new drug for NRG protects mitochondria and increases the viability of human cells, potentially preventing or significantly slowing disease progression
in patients with Parkinson's disease or ALS.
Currently, treatments for Parkinson's disease can only provide symptom management
.
The press release notes that if successful in clinical trials, NRG's innovative therapies will be the first disease-modifying drugs
that can prevent or delay disease progression in Parkinson's patients.
In addition, Professor Seth Masters, NRG's Vice President of Discovery Biology, discovered a novel pathological mechanism
targeting ALS in the NRG pipeline.
TDP-43, a protein associated with sporadic and familial ALS, is able to trigger neuroinflammation
by activating the innate immune sensor STING.
Dr.
Neil Miller, co-founder and CEO of NRG Therapeutics, said, "We look forward to working with new and existing investors, our expanding team and R&D partners to bring new drugs and hope
to the growing number of neurodegenerative disease patients around the world.
"
WuXi AppTec provides integrated, end-to-end new drug development and manufacturing services to the global biopharmaceutical industry, covering chemical drug development and manufacturing, biological research, preclinical testing and clinical trial development, cell and gene therapy development, testing and manufacturing
.
If you have relevant business needs, please click the picture below to fill in the specific information
.
▲If you have any business needs, please press and hold to scan the QR code above, or
.
NRG is developing disease modification therapies based on mitochondrial biology to slow or halt the progression
of neurodegenerative diseases such as Parkinson's disease and amyotrophic lateral sclerosis (ALS).
The funding will be used to advance INDs
for its potential "first-in-class" brain-permeable small molecule therapy candidates, the press release said.
Parkinson's disease is one of the fastest-growing neurological disorders in the world and is caused
by the loss of specific dopamine-producing cells in the brain that control muscle movement.
ALS is a rare fatal neurodegenerative disease in which patients usually die
within 3-5 years of diagnosis.
Currently commercially available ALS disease-modifying therapies can prolong survival by about 3-6 months, and these patients urgently need disease-modifying drugs
that can further prolong survival.
Mitochondria are essential for maintaining the health of cells by
powering them.
There is plenty of evidence that mitochondrial failure, or dysfunction, is common
in many degenerative diseases.
In recent years, mitochondrial permeability transition pore (mPTP) has been implicated
in the formation of such diseases.
The micro-turn on of mPTP allows key related proteins that lead to Parkinson's disease and ASL to enter the mitochondria and release mitochondrial DNA into the
cytoplasm.
The immune system then recognizes this DNA as a foreign invader, leading to a large amount of inflammation and the death
of downstream neurons.
In preclinical disease models, inhibition of mPTP has been shown to protect neurons, reduce neuroinflammation, and prolong survival
.
mPTP is a key driver of Parkinson's disease and ALS disease pathology (Image: NRGTherapeutics).
NRG's preclinical pipeline includes small molecule candidate therapies
that inhibit mPTP through novel mechanisms of action.
This small molecule acts like a kind of biological "tape" that prevents the opening of mPTP and thus mitochondrial damage
.
In vitro studies have shown that the investigational new drug for NRG protects mitochondria and increases the viability of human cells, potentially preventing or significantly slowing disease progression
in patients with Parkinson's disease or ALS.
Currently, treatments for Parkinson's disease can only provide symptom management
.
The press release notes that if successful in clinical trials, NRG's innovative therapies will be the first disease-modifying drugs
that can prevent or delay disease progression in Parkinson's patients.
In addition, Professor Seth Masters, NRG's Vice President of Discovery Biology, discovered a novel pathological mechanism
targeting ALS in the NRG pipeline.
TDP-43, a protein associated with sporadic and familial ALS, is able to trigger neuroinflammation
by activating the innate immune sensor STING.
Dr.
Neil Miller, co-founder and CEO of NRG Therapeutics, said, "We look forward to working with new and existing investors, our expanding team and R&D partners to bring new drugs and hope
to the growing number of neurodegenerative disease patients around the world.
"
WuXi AppTec provides integrated, end-to-end new drug development and manufacturing services to the global biopharmaceutical industry, covering chemical drug development and manufacturing, biological research, preclinical testing and clinical trial development, cell and gene therapy development, testing and manufacturing
.
If you have relevant business needs, please click the picture below to fill in the specific information
.
▲If you have any business needs, please press and hold to scan the QR code above, or
